Eupraxia Pharmaceuticals Inc. (EPRX) on Tuesday reported positive 36-week data from the highest dose cohort in its ongoing Phase 1b/2a RESOLVE trial evaluating EP-104GI for eosinophilic esophagitis.
In the highest dose cohort, EoEHSS Stage and Grade scores were reduced by 0.59 and 0.53, representing declines of 90% and 88%, respectively, indicating improvements across both inflammatory and structural components of the disease.
Peak Eosinophil Count fell 72% from baseline at week 36, marking the largest reduction observed across all dose cohorts.
The company said EP-104GI continued to be well tolerated, with no drug-related serious adverse events reported among 31 patients treated and more than 230 patient-months of follow-up.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.